";s:4:"text";s:4289:" Induction of thymidine Phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO). Capecitabine and the fluorouracil precursors 5′-deoxy-5-fluorocytidine and 5′-deoxy-5-fluorouridine do not accumulate significantly in plasma after repeated administration. Pectasides D, Karavasilis V, Papaxoinis G et al. Ratain MJ, Eisen T, Stadler WM et al. Sawada N, Ishikawa T, Fukase Y et al. Cancer Res 1993; 53: 5433–8Takimoto CH, Lu ZH, Zhang R, et al. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. You can also search for this author in Invest New Drugs 1989; 7: 13–25Christophidis N, Vajda FJE, Lucas I, et al.
A phase III trial (SO 14796) of Xeloda® (capecitabine) in previously untreated advanced/metastatic colorectal cancer [abstract]. 1998; 12(10 Suppl.
In: DeVita VT Jr, Hellman S, Rosenberg SA eds.
Am J Clin Oncol 1995; 18: 118–25Hryniuk WM, Figueredo A, Goodyear M. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Capecitabine Pharmacokinetics Absorption Bioavailability. 21. Favaro JP, George DJ. Ishikawa T, Sekiguchi F, Fukase Y et al. Dear doctor letter regarding safety information for use of Xeloda37. Population study of dihydropyrimidine dehydrogenase in cancer patients. Capecitabine bioequivalence in healthy volunteers. Effect of an antacid on gastrointestinal absorption of theophylline. Physician data query (database). Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Govindarajan R, Adusumilli J, Baxter DL et al. Pharmacol Ther 1991; 52: 35–84Ringel I, Horwitz SB. plasma concentration, AUC, C max , steady-state concentrations) and toxicity for many other cancer chemotherapeutic agents have been reported [ 7 – 10 ]. Kang Y, Kang WK, Shin DB et al.
Br J Cancer 2000; 83: 22–9Kolesar JM, Johnson CL, Freeberg BL, et al. [Docket No. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Clin Cancer Res 1998; 4: 941–8Reigner B, Clive S, Cassidy J, et al. Trastuzumab and capecitabine for metastatic breast cancer. In: DiPiro JT, Talbert RL, Hayes PE, et al., editors. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. High-fat meal reduces bioavailability by about 29%. Roche Laboratories. Semin Oncol 1987; 14: 3–11Diasio RB.
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.
Wilhelm SM, Carter C, Tang L et al. Common side effects of Xeloda include: severe nausea or vomiting (may be severe), ; stomach pain or upset, loss of appetite, ; constipation, tiredness, weakness, ; back/joint/muscle pain, Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Accessed 2013 Sept 16.. Accessed 2006 Feb 10. http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm4. Brugarolas J. Renal-cell carcinoma—molecular pathways and therapies. 21. 46. Pfizer Inc. Paclitaxel injection prescribing information. 25. Reigner B, Verweij J, Dirix L et al. 15. Xeloda (capecitabine) is an antineoplastic (anti-cancer) medication used to treat breast cancer and colon or rectum cancer that has spread to other parts of the body. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Escudier B, Eisen T, Stadler WM et al. In: van Boxtel CJ, Holford NHG, Danhof M, editors. Capecitabine was designed to limit plasma concentrations of 5-FU by allowing 5-FU to be selectively synthesized in the tumour. Bethesda, MD: Food and Drug Administration; 1998 Mar 19.20.